Stock Updates

Is this Large Market Cap Stock target price reasonable for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)?

The company in question is, Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) currently with a stock price of 141.92 (-1.51% today). The market cap for Intercept Pharmaceuticals, Inc. is 3580.89, and is in the sector Healthcare, and Biotechnology industry. The target price for Intercept Pharmaceuticals, Inc. is 212.84. Currently Intercept Pharmaceuticals, Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Intercept Pharmaceuticals, Inc. is 383.55 and so far today it is 147915.

Performance in the last year for Intercept Pharmaceuticals, Inc. has been -15.20%. For EPS growth, Intercept Pharmaceuticals, Inc. has seen a growth of 29.90%, and is looking to grow in the next year to 9.40%. More long term stats show that EPS growth has been -59.20% over the last five years and could be 7.00% for the next five years. Intercept Pharmaceuticals, Inc. has seen sales growth quarter over quarter at 1140.40%, with EPS growth quarter over quarter at -57.50%. The 20-day simple moving average is -10.11%, with the 200-day simple moving average coming to 0.25%.

Since the IPO date for Intercept Pharmaceuticals, Inc. on the 10/11/2012, Intercept Pharmaceuticals, Inc. has seen performance year to date to be -3.52%. With Intercept Pharmaceuticals, Inc. trading at 141.92, the dividend yield is *TBA, and the EPS is -14.04.

So could Intercept Pharmaceuticals, Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 518.97 and the P/B is at 8.51. The P/cash is 8.15, with P/free cash flow at *TBA.

Intercept Pharmaceuticals, Inc. ability to deal with debt shows that the current ratio is 4.9, and the quick ratio is 4.9. This is with long term debt/equity at 0, and total debt/equity at 0.

In terms of margins, Intercept Pharmaceuticals, Inc. has a gross margin of *TBA, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Intercept Pharmaceuticals, Inc. is *TBA. Return on assets come to -55.10% with return on investment coming to -38.10%.

Insider ownership for Intercept Pharmaceuticals, Inc., is at 2.90% and institutional ownership comes to 84.00%. Outstanding shares are at 24.85. While shares float is 17.56. The float short is currently 23.40%, and short ratio is 10.71.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Mark Hines

Leave a Comment